Takahisa Hiramitsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takahisa Hiramitsu has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Kenta Futamura
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
26 shared publicationsYoshihiko Watarai
Departments of Transplant Surgery, Transplant Medicine, and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital , Nagoya
24 shared publicationsManabu Okada
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan
21 shared publicationsShunji Narumi
Departments of Transplant Surgery, Transplant Medicine, and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital , Nagoya
21 shared publicationsNorihiko Goto
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
18 shared publicationsToshihiro Ichimori
Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan
17 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Predicting native kidney volume regression after transplantation in autosomal-dominant polycystic kidney disease
Background: Native polycystic kidneys often regress after kidney transplantation in patients with autosomal-dominant polycystic kidney disease (ADPKD), but the degree of regression varies widely, and no externally validated preoperative prediction model is available. Therefore, we aimed to develop and externally validate a preoperative model to predict post-transplant native kidney volume changes. Methods: This multicentre, retrospective study included 224 patients with ADPKD who underwent kidney transplantation at 11 Japanese centres. Patients were divided by centre into non-overlapping development (four centres, n = 164) and validation (seven centres, n = 60) sets. Total kidney volume (TKV) was measured before and 1 year after transplantation. The TKV change ratio (TKVCR) was calculated as post-transplantation TKV divided by baseline TKV. Multivariable linear regression was used to identify preoperative predictors. Results: The final model included five preoperative predictors: body mass index, age², log₁₀(TKV), systolic blood pressure, and log₁₀(dialysis duration + 1) (R²=0.168). On external validation, the R² was 0.255, mean absolute error was 0.122, and root mean squared error was 0.154; however, individual-level prediction was limited. In an exploratory binary classification using the overall cohort mean TKVCR (0.62) as the cutoff, accuracy was 0.783, negative predictive value was 0.862, and the area under the receiver operating characteristic curve was 0.850 (95% confidence interval, 0.743–0.947). Conclusions: Preoperative factors were associated with post-transplant native kidney volume change, but accuracy for individual patients was limited. These findings provide preliminary evidence that volume changes may be partly predictable.
- 22 October 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (11)
Open AccessPredicting native kidney volume regression after transplantation in autosomal-dominant polycystic kidney disease
Background: Native polycystic kidneys often regress after kidney transplantation in patients with autosomal-dominant polycystic kidney disease (ADPKD), but the degree of regression varies widely, and no externally validated preoperative prediction model is available. Therefore, we aimed to develop and externally validate a preoperative model to predict post-transplant native kidney volume changes. Methods: This multicentre, retrospective study included 224 patients with ADPKD who underwent kidney transplantation at 11 Japanese centres. Patients were divided by centre into non-overlapping development (four centres, n = 164) and validation (seven centres, n = 60) sets. Total kidney volume (TKV) was measured before and 1 year after transplantation. The TKV change ratio (TKVCR) was calculated as post-transplantation TKV divided by baseline TKV. Multivariable linear regression was used to identify preoperative predictors. Results: The final model included five preoperative predictors: body mass index, age², log₁₀(TKV), systolic blood pressure, and log₁₀(dialysis duration + 1) (R²=0.168). On external validation, the R² was 0.255, mean absolute error was 0.122, and root mean squared error was 0.154; however, individual-level prediction was limited. In an exploratory binary classification using the overall cohort mean TKVCR (0.62) as the cutoff, accuracy was 0.783, negative predictive value was 0.862, and the area under the receiver operating characteristic curve was 0.850 (95% confidence interval, 0.743–0.947). Conclusions: Preoperative factors were associated with post-transplant native kidney volume change, but accuracy for individual patients was limited. These findings provide preliminary evidence that volume changes may be partly predictable.
- 11 August 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 647-658
Laterality of Hand-Assisted Laparoscopic Donor Nephrectomy in Adult Kidney Transplantation
- 11 August 2026
- Published by Elsevier in Journal of Surgical Research
- Vol. 326, 647-658
Laterality of Hand-Assisted Laparoscopic Donor Nephrectomy in Adult Kidney Transplantation
- Open Access
- 16 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901912
Editorial: Current perspectives in the diagnosis of parathyroid disease, volume II
Parathyroid diseases encompass a diverse and complex range of endocrine disorders, ranging from asymptomatic biochemical abnormalities to aggressive conditions associated with severe systemic complications. Recent advances in biochemical assays and imaging modalities have substantially improved the detection of parathyroid disorders. Nevertheless, significant diagnostic challenges remain, including the accurate localization of lesions, reliable risk stratification, and the integration of diagnostic data into individualized clinical decision-making.The second volume of the Research Topic "Current Perspectives in the Diagnosis of Parathyroid Disease" presents a collection of original research articles and comprehensive reviews that collectively demonstrate the evolving concept of diagnosis in parathyroid disease. Rather than focusing solely on biochemical confirmation or anatomical localization, this volume highlights a broader and more integrative diagnostic framework that incorporates biological heterogeneity, prognostic assessment, and emerging technological approaches.In patients with primary hyperparathyroidism (PHPT), treatment decisions have traditionally been guided by biochemical profiles and symptomatic presentations. However, these conventional approaches cannot detect subclinical organ damage or predict disease progression. A previous review by Zhu et al. provided a comprehensive synthesis of emerging multilevel biomarkers for PHPT, including genetic and epigenetic alterations, non-coding RNAs, metabolic profiles, inflammatory markers, and advanced imaging features. The use of such dynamic biomarker profiling can facilitate precise risk stratification and support individualized treatment strategies. Furthermore, by proposing an integrated framework that combines dynamic biomarker assessment with multidisciplinary teambased decision-making, personalized surgical planning and long-term surveillance can be facilitated. This study underscores a significant conceptual shift from traditional uniform approaches toward personalized interventions and long-term surveillance.In PHPT, preoperative localization of the pathological parathyroid glands (PTGs) remains a persistent challenge in minimally invasive parathyroidectomy (PTx). Kang This study did not receive any specific grants from funding agencies in public, commercial, non-119 profit sectors. 120
- 16 June 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1901912
Open AccessEditorial: Current perspectives in the diagnosis of parathyroid disease, volume II
Parathyroid diseases encompass a diverse and complex range of endocrine disorders, ranging from asymptomatic biochemical abnormalities to aggressive conditions associated with severe systemic complications. Recent advances in biochemical assays and imaging modalities have substantially improved the detection of parathyroid disorders. Nevertheless, significant diagnostic challenges remain, including the accurate localization of lesions, reliable risk stratification, and the integration of diagnostic data into individualized clinical decision-making.The second volume of the Research Topic "Current Perspectives in the Diagnosis of Parathyroid Disease" presents a collection of original research articles and comprehensive reviews that collectively demonstrate the evolving concept of diagnosis in parathyroid disease. Rather than focusing solely on biochemical confirmation or anatomical localization, this volume highlights a broader and more integrative diagnostic framework that incorporates biological heterogeneity, prognostic assessment, and emerging technological approaches.In patients with primary hyperparathyroidism (PHPT), treatment decisions have traditionally been guided by biochemical profiles and symptomatic presentations. However, these conventional approaches cannot detect subclinical organ damage or predict disease progression. A previous review by Zhu et al. provided a comprehensive synthesis of emerging multilevel biomarkers for PHPT, including genetic and epigenetic alterations, non-coding RNAs, metabolic profiles, inflammatory markers, and advanced imaging features. The use of such dynamic biomarker profiling can facilitate precise risk stratification and support individualized treatment strategies. Furthermore, by proposing an integrated framework that combines dynamic biomarker assessment with multidisciplinary teambased decision-making, personalized surgical planning and long-term surveillance can be facilitated. This study underscores a significant conceptual shift from traditional uniform approaches toward personalized interventions and long-term surveillance.In PHPT, preoperative localization of the pathological parathyroid glands (PTGs) remains a persistent challenge in minimally invasive parathyroidectomy (PTx). Kang This study did not receive any specific grants from funding agencies in public, commercial, non-119 profit sectors. 120
- Open Access
- 25 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784083
Clinical management of cancer after kidney transplantation
Advances in immunosuppressive therapy have markedly improved short-term graft survival post-kidney transplantation (KT); however, these advances have also profoundly altered long-term disease patterns in transplant recipients. Cancer remains a major barrier limiting improvements in long-term survival. Kidney transplant recipients are at increased risk of malignancy owing to impaired graft function and immunosuppressive medications. To improve cancer-related outcomes, comprehensive strategies encompassing prevention, early detection through screening, and appropriate treatment are required. Primary prevention includes the appropriate selection and maintenance of immunosuppressive medications, careful consideration of KT indications for recipients and donors with previously treated cancers, and vaccination. Secondary prevention requires effective, risk-adapted cancer screening in high-risk kidney transplant recipients. Following a cancer diagnosis, management includes localized resection and systemic therapy for primary, recurrent, or refractory disease. Systemic therapy includes chemotherapy and immunotherapy, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, which may affect graft function and cause treatment-specific adverse effects. Additionally, immunosuppressive medications often require modification to minimize the risk of graft rejection while maintaining a low likelihood of recurrence. In this review, we summarize current strategies for cancer prevention, screening, and treatment following KT.
- 25 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1784083
Open AccessClinical management of cancer after kidney transplantation
Advances in immunosuppressive therapy have markedly improved short-term graft survival post-kidney transplantation (KT); however, these advances have also profoundly altered long-term disease patterns in transplant recipients. Cancer remains a major barrier limiting improvements in long-term survival. Kidney transplant recipients are at increased risk of malignancy owing to impaired graft function and immunosuppressive medications. To improve cancer-related outcomes, comprehensive strategies encompassing prevention, early detection through screening, and appropriate treatment are required. Primary prevention includes the appropriate selection and maintenance of immunosuppressive medications, careful consideration of KT indications for recipients and donors with previously treated cancers, and vaccination. Secondary prevention requires effective, risk-adapted cancer screening in high-risk kidney transplant recipients. Following a cancer diagnosis, management includes localized resection and systemic therapy for primary, recurrent, or refractory disease. Systemic therapy includes chemotherapy and immunotherapy, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy, which may affect graft function and cause treatment-specific adverse effects. Additionally, immunosuppressive medications often require modification to minimize the risk of graft rejection while maintaining a low likelihood of recurrence. In this review, we summarize current strategies for cancer prevention, screening, and treatment following KT.
- Open Access
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1678309
Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant
Introduction: The incidence of cancer after kidney transplantation (KT) increases owing to the use of immunosuppressive (IS) medications, which may lead to death with a functioning graft (DWFG) and reduced long-term graft survival. However, the effect of IS medications, including their blood levels, on cancer development before graft failure remains underexplored. Methods: This single-center retrospective cohort study involved 1274 living-donor KTs performed between January 2008 and December 2021. Cancer was diagnosed in 141 recipients before graft failure. DWFG and mortality-free survival were compared between recipients with and those without cancer before graft failure. Multivariable Cox regression analysis was used to identify risk factors for cancer. Trough levels of IS medications (calcineurin inhibitors and mycophenolate mofetil) were compared between recipients with and those without cancer. The effect of cancer detection (screening, incidental, or symptomatic) on DWFG was also evaluated. Results: DWFG and recipient mortality events were more common in the cancer group than in the non-cancer group. A significant risk factor for cancer was older recipient age ( P < 0.001; hazard ratio, 1.066). IS medication levels were similar between the cancer and non-cancer groups. Recipients with cancer detected through screening had lower DWFG rates than those with cancer detected incidentally or symptomatically. Discussion: IS medication level was not a significant risk factor for cancer before graft failure. Nevertheless, cancer risk after KT significantly increased both DWFG and recipient mortality rates. Cancer screening may help reduce the incidence of DWFG and recipient mortality associated with cancer.
- 9 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1678309
Open AccessRisk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant
Introduction: The incidence of cancer after kidney transplantation (KT) increases owing to the use of immunosuppressive (IS) medications, which may lead to death with a functioning graft (DWFG) and reduced long-term graft survival. However, the effect of IS medications, including their blood levels, on cancer development before graft failure remains underexplored. Methods: This single-center retrospective cohort study involved 1274 living-donor KTs performed between January 2008 and December 2021. Cancer was diagnosed in 141 recipients before graft failure. DWFG and mortality-free survival were compared between recipients with and those without cancer before graft failure. Multivariable Cox regression analysis was used to identify risk factors for cancer. Trough levels of IS medications (calcineurin inhibitors and mycophenolate mofetil) were compared between recipients with and those without cancer. The effect of cancer detection (screening, incidental, or symptomatic) on DWFG was also evaluated. Results: DWFG and recipient mortality events were more common in the cancer group than in the non-cancer group. A significant risk factor for cancer was older recipient age ( P < 0.001; hazard ratio, 1.066). IS medication levels were similar between the cancer and non-cancer groups. Recipients with cancer detected through screening had lower DWFG rates than those with cancer detected incidentally or symptomatically. Discussion: IS medication level was not a significant risk factor for cancer before graft failure. Nevertheless, cancer risk after KT significantly increased both DWFG and recipient mortality rates. Cancer screening may help reduce the incidence of DWFG and recipient mortality associated with cancer.
- 13 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (8) , 1574-1580
Perioperative Severe Complications Can Cause Pancreatic Graft Failure and Mortality in Pancreas Transplantation
- 13 June 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (8) , 1574-1580
Perioperative Severe Complications Can Cause Pancreatic Graft Failure and Mortality in Pancreas Transplantation
- 25 April 2025
- Published by SAGE Publications in Videoscopy™
- Vol. 35 (1) , 1-2
A Simple Seven-Step Operative Method for Hand-Assisted Laparoscopic Donor Nephrectomy in Living Donor Kidney Transplantation
Introduction: Living donor kidney transplant (LDKT) addresses the significant shortage of cadaveric donors for kidney transplantation (KT). Since living kidney donors (LKDs) are healthy individuals, LDKT surgery must be safe and minimally invasive. Therefore, the development of a simple surgical method to avoid peri- and postoperative complications is essential. Herein, we present a simple seven-step operative method for left- and right-hand-assisted laparoscopic donor nephrectomy (HALDN) in a step-by-step manner. Methods: For left HALDN, the LKD was positioned in a right semi-lateral decubitus position. A 7.5 cm incision was made in the upper middle abdomen for the hand port. For the laparoscope, a 1 cm incision was made on the left caudal side of the umbilicus. Subsequently, another 1 cm incision was made in the left lower abdomen for the dissecting instruments. The operative procedures were as follows: (1) mobilization of the descending colon and spleen, (2) dissection of the left ureter and gonadal vein, (3) detachment of the left adrenal gland from the left kidney along with transection of the left adrenal vein, (4) exposure of the left renal artery and vein including transection of the lumbar vein, (5) transection of the left ureter and gonadal vein, (6) transection of the left renal artery and vein using a laparoscopic vascular stapler, and (7) extraction of the kidney. For the right HALDN, the LKD was positioned in a left semi-lateral decubitus position. A 7.5 cm incision was made in the right lower abdomen for the hand port. For the laparoscope, a 1 cm incision was made on the right cranial side of the umbilicus. Then, another 1 cm incision was made in the right upper abdomen for the instrument. The operative procedures were as follows: (1) mobilization of the ascending colon and duodenum to expose the inferior vena cava and renal vein, (2) dissection of the right ureter and gonadal vein, (3) mobilization of the right kidney, (4) exposure of the right renal artery and vein, (5) transection of the right ureter and gonadal vein, (6) transection of the right renal artery and vein using endoscopic vascular staplers, and (7) extraction of the kidney. Results: Between January 2008 and December 2024, these operative methods were applied to 1,453 and 126 LKDs for left and right HALDN, respectively. The median operative time (interquartile range) was 195.0 minutes (156.0–228.0 minutes) and 186.0 minutes (159.0–220.0 minutes) for left and right HALDN, respectively. Blood loss (interquartile range) was 20.0 mL (10.0–35.0 mL) and 20.0 mL (10.0–40.0 mL) for left and right HALDN, respectively. Open conversion was performed in two LKDs for left HALDN and one LKD for right HALDN due to vascular injuries. No surgery-related deaths occurred. Conclusion: These simple seven-step operative methods allow a safe and minimally invasive HALDN for LDKT. Patient Consent Statement: All recipient data were retrospectively collected from the medical records and analyzed anonymously. Therefore, the need for informed consent was waived. Author Disclosure Statement: None of the authors have conflicts of interest to disclose. Authors received and archived patient consent for video recording/publication prior to video recording of the procedure. Runtime of video: 9 mins 53 secs.
- 25 April 2025
- Published by SAGE Publications in Videoscopy™
- Vol. 35 (1) , 1-2
A Simple Seven-Step Operative Method for Hand-Assisted Laparoscopic Donor Nephrectomy in Living Donor Kidney Transplantation
Introduction: Living donor kidney transplant (LDKT) addresses the significant shortage of cadaveric donors for kidney transplantation (KT). Since living kidney donors (LKDs) are healthy individuals, LDKT surgery must be safe and minimally invasive. Therefore, the development of a simple surgical method to avoid peri- and postoperative complications is essential. Herein, we present a simple seven-step operative method for left- and right-hand-assisted laparoscopic donor nephrectomy (HALDN) in a step-by-step manner. Methods: For left HALDN, the LKD was positioned in a right semi-lateral decubitus position. A 7.5 cm incision was made in the upper middle abdomen for the hand port. For the laparoscope, a 1 cm incision was made on the left caudal side of the umbilicus. Subsequently, another 1 cm incision was made in the left lower abdomen for the dissecting instruments. The operative procedures were as follows: (1) mobilization of the descending colon and spleen, (2) dissection of the left ureter and gonadal vein, (3) detachment of the left adrenal gland from the left kidney along with transection of the left adrenal vein, (4) exposure of the left renal artery and vein including transection of the lumbar vein, (5) transection of the left ureter and gonadal vein, (6) transection of the left renal artery and vein using a laparoscopic vascular stapler, and (7) extraction of the kidney. For the right HALDN, the LKD was positioned in a left semi-lateral decubitus position. A 7.5 cm incision was made in the right lower abdomen for the hand port. For the laparoscope, a 1 cm incision was made on the right cranial side of the umbilicus. Then, another 1 cm incision was made in the right upper abdomen for the instrument. The operative procedures were as follows: (1) mobilization of the ascending colon and duodenum to expose the inferior vena cava and renal vein, (2) dissection of the right ureter and gonadal vein, (3) mobilization of the right kidney, (4) exposure of the right renal artery and vein, (5) transection of the right ureter and gonadal vein, (6) transection of the right renal artery and vein using endoscopic vascular staplers, and (7) extraction of the kidney. Results: Between January 2008 and December 2024, these operative methods were applied to 1,453 and 126 LKDs for left and right HALDN, respectively. The median operative time (interquartile range) was 195.0 minutes (156.0–228.0 minutes) and 186.0 minutes (159.0–220.0 minutes) for left and right HALDN, respectively. Blood loss (interquartile range) was 20.0 mL (10.0–35.0 mL) and 20.0 mL (10.0–40.0 mL) for left and right HALDN, respectively. Open conversion was performed in two LKDs for left HALDN and one LKD for right HALDN due to vascular injuries. No surgery-related deaths occurred. Conclusion: These simple seven-step operative methods allow a safe and minimally invasive HALDN for LDKT. Patient Consent Statement: All recipient data were retrospectively collected from the medical records and analyzed anonymously. Therefore, the need for informed consent was waived. Author Disclosure Statement: None of the authors have conflicts of interest to disclose. Authors received and archived patient consent for video recording/publication prior to video recording of the procedure. Runtime of video: 9 mins 53 secs.
- Open Access
- 15 October 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 413-415
A novel technique for pancreatic-juice drainage to the remaining graft duodenum after blood reperfusion in pancreas transplantation
- 15 October 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 48 (1) , 413-415
Open AccessA novel technique for pancreatic-juice drainage to the remaining graft duodenum after blood reperfusion in pancreas transplantation
- Open Access
- 21 June 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1444651
Editorial: Recent advances in the treatment of parathyroid disease
- 21 June 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1444651
Open AccessEditorial: Recent advances in the treatment of parathyroid disease
- Open Access
- 1 February 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (5) , 1321-1332
Impact of Age 70 years or Older on Donors for Living-Donor Kidney Transplantation
- 1 February 2024
- Published by Elsevier in Kidney International Reports
- Vol. 9 (5) , 1321-1332
Open AccessImpact of Age 70 years or Older on Donors for Living-Donor Kidney Transplantation